Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Clearside reports Phase II DME data for CLS-TA

Clearside Biomedical Inc. (NASDAQ:CLSD) reported that suprachoroidal CLS-TA plus Eylea aflibercept led to a smaller gain in visual acuity and a greater incidence of both elevated intraocular pressure and cataracts compared with Eylea alone in the Phase II TYBEE trial to treat diabetic macular edema

Read the full 450 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers